Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-04-05
1999-05-25
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31495
Patent
active
059069880
ABSTRACT:
Piperazine derivatives, particularly ranolazine, are useful for treatment of tissues experiencing a physical or chemical insult, and specifically for treating cardioplegia, hypoxic and/or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants.
REFERENCES:
patent: 4567264 (1986-01-01), Kluge et al.
M.C. Allely et al., "The Effects of the Novel Anti-anginal Compound RS-43285 on Myocardial Conduction in the Anaesthetized Dog", Br. J. Pharmacol., 93, 375-382 (1988).
M.C. Allely et la., "The Effects of the Novel Anti-anginal Agent Ranolazine (I.D.) In a Canine Model of Transient Myocardial Ischaemia", Br. J. Pharmacol., 93, 246P (1988).
P. Ferrendon et al., "Protective Effects of the Novel Anti-ischaemic Agent Ranolazine (RS-43285) in Perfused Rat Hearts", Br. J. Pharmacol., 93, 247P (1988).
C.M. Brown et al., "Pharmacological Profile of Ranolazine, a Metabolic Modulator Active in Ischaemia", Br. J. Pharmacol., 93, 248P (1988).
M.C. Allely et al., "The Effects of the Novel Anti-anginal Agent Ranolazine Myocardial Ischaemia", Biochem. Soc. Trans., 15, 1057-1058 (1987).
D. Jain et al., "Preliminary Study of a New Anti-anginal Agent (RS-43285, Syntex)", Cardiovascular Drugs Ther., 1, 252 (1987).
E. Boddeke et al., "New Anti-ischaemic Drugs: Cytoprotective Action with No Primary Harmodynamic Effects", Trends in Pharmacol. Sci., 10(10), 397-400 (1989).
D. Anaise et al., "The Protective Effects of Calcium Inhibitors and of Captopril on the Renal Microcirculation During Reperfusion", Transplantation, 43(1), 128-133 (1987).
A. Wauquier et al., "Brain Ischemia as a Target for Ca.sup.2+ Entry Blockers", Ann. N.Y. Acad. Sci., 522, 478-190 (1988).
D. Jain et al., "RS-43285 (Syntex) A Preliminary Study of a Unigue Anti-anginal Agent", Clin. Sci. , 73(17), 136 (1987).
Martindale, The Extra Pharmacopoeia, 28th ed., J.E.F. Reynolds et al., eds., The Pharmaceutical Press, London (1982), p. 636, No. 3746-e.
Dow Robert James
Ferrandon Pierre
Fay Zohreh
Syntex (U.S.A.) Inc.
LandOfFree
Methods of treatment using ranolazine and related piperazine der does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using ranolazine and related piperazine der, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using ranolazine and related piperazine der will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-401420